Viewing Study NCT04274933


Ignite Creation Date: 2025-12-25 @ 2:59 AM
Ignite Modification Date: 2025-12-31 @ 5:25 AM
Study NCT ID: NCT04274933
Status: TERMINATED
Last Update Posted: 2020-10-29
First Post: 2020-02-17
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy
Sponsor:
Organization:

Study Design

Study Type: INTERVENTIONAL
Expanded Access Type Individual: None
Expanded Access Type Intermediate: None
Expanded Access Type Treatment: None
Patient Registry: None
Target Duration: None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention: None
Bio Spec Description: None
Enrollment Count:
Enrollment Type:
Design Primary Purpose:
Design Masking:
Phases:

Phases

Phase Brief Phase Text View
None PHASE1 View
Observational Models:
Time Perspective List:
Who Masked List: